论文部分内容阅读
免疫学研究的进展,已使免疫学检测成为对肿瘤患者疗效与预后判断的指标。一些事实表明,肿瘤治疗的预后与机体免疫功能有密切关系。临床治愈后的肿瘤患者,细胞免疫功能正常或迅速恢复者,转移复发率较低,而生存期较长。显然改善放、化疗后肿瘤患者的免疫功能损害,对于提高疗效有不可忽视的作用。PHA 做为一种非特异性免疫制剂,用于治疗血液病、传染性及免疫缺陷疾病等,均已取得一定的疗效。本文用 PHA 对放、化疗后肿瘤患者进行免疫治疗,通过对疗前后检测免疫指标的改变,以观察 PHA 对肿瘤患者免疫功能的影响。报导如下:
Advances in immunological research have made immunological testing an indicator of the efficacy and prognosis of cancer patients. Some facts indicate that the prognosis of cancer treatment is closely related to the body’s immune function. Patients with clinically cured tumors, with normal or rapidly recovering cellular immune functions, have a lower metastatic recurrence rate and a longer survival period. Obviously improving the immune function of cancer patients after radiotherapy and chemotherapy has a significant effect on improving the curative effect. PHA has been used as a non-specific immune preparation for the treatment of hematological diseases, infectious diseases and immunodeficiency diseases. In this article, PHA was used for immunotherapy of cancer patients after radiotherapy and chemotherapy. Changes in immune parameters were measured before and after treatment to observe the effect of PHA on the immune function of cancer patients. The report is as follows: